These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17694448)

  • 1. Treating HIV-1 infection with dendritic cells.
    Connolly NC; Colleton BA; Rinaldo CR
    Curr Opin Mol Ther; 2007 Aug; 9(4):353-63. PubMed ID: 17694448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1.
    García F; Routy JP
    Vaccine; 2011 Sep; 29(38):6454-63. PubMed ID: 21791232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based human immunodeficiency virus vaccine.
    Rinaldo CR
    J Intern Med; 2009 Jan; 265(1):138-58. PubMed ID: 19093966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic Cells, the Double Agent in the War Against HIV-1.
    Martín-Moreno A; Muñoz-Fernández MA
    Front Immunol; 2019; 10():2485. PubMed ID: 31708924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy.
    Reis EC; da Silva LT; da Silva WC; Rios A; Duarte AJ; Oshiro TM; Crovella S; Pontillo A
    Hum Vaccin Immunother; 2018; 14(8):1995-2002. PubMed ID: 29641325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?
    da Silva LT; Santillo BT; de Almeida A; Duarte AJDS; Oshiro TM
    Front Immunol; 2018; 9():2993. PubMed ID: 30619346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
    Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
    J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in dendritic cell immunotherapies for HIV-1 infection.
    Miller E; Bhardwaj N
    Expert Opin Biol Ther; 2014 Nov; 14(11):1545-9. PubMed ID: 25143151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1.
    Walsh SR; Bhardwaj N; Gandhil RT
    Curr HIV Res; 2003 Apr; 1(2):205-16. PubMed ID: 15043203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
    Connolly NC; Whiteside TL; Wilson C; Kondragunta V; Rinaldo CR; Riddler SA
    Clin Vaccine Immunol; 2008 Feb; 15(2):284-92. PubMed ID: 17942609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection.
    Fan Z; Huang XL; Kalinski P; Young S; Rinaldo CR
    Clin Vaccine Immunol; 2007 Sep; 14(9):1127-37. PubMed ID: 17634507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection.
    Espinar-Buitrago M; Muñoz-Fernández MA
    Front Immunol; 2021; 12():719664. PubMed ID: 35058917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future considerations for dendritic cell immunotherapy against chronic viral infections.
    Atanley E; van Drunen Littel-van den Hurk S
    Expert Rev Clin Immunol; 2014 Jun; 10(6):801-13. PubMed ID: 24734867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DC-based immunotherapy as strategy to purge the HIV reservoir?
    Søgaard OS
    EBioMedicine; 2019 May; 43():16-17. PubMed ID: 30981650
    [No Abstract]   [Full Text] [Related]  

  • 16. DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.
    de Goede AL; Andeweg AC; van den Ham HJ; Bijl MA; Zaaraoui-Boutahar F; van IJcken WF; Wilgenhof S; Aerts JL; Gruters RA; Osterhaus AD;
    Vaccine; 2015 Jun; 33(25):2922-9. PubMed ID: 25913415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Dendritic Cells in Natural Immune Control of HIV-1 Infection.
    Martin-Gayo E; Yu XG
    Front Immunol; 2019; 10():1306. PubMed ID: 31244850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.
    Melki MT; Saïdi H; Dufour A; Olivo-Marin JC; Gougeon ML
    PLoS Pathog; 2010 Apr; 6(4):e1000862. PubMed ID: 20419158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell based vaccines for HIV infection: the way ahead.
    García F; Plana M; Climent N; León A; Gatell JM; Gallart T
    Hum Vaccin Immunother; 2013 Nov; 9(11):2445-52. PubMed ID: 23912672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy.
    Moura Rodrigues R; Plana M; Garcia F; Zupin L; Kuhn L; Crovella S
    Immunol Res; 2016 Dec; 64(5-6):1207-1215. PubMed ID: 27704462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.